NanoString Technologies Stock Price, News & Analysis (NASDAQ:NSTG)

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies Inc (NASDAQ:NSTG) issued its earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.55) by $0.02. The biotechnology company earned $30.35 million during the quarter, compared to analyst estimates of $29 million. NanoString Technologies had a negative net margin of 68.16% and a negative return on equity of 118.03%. View NanoString Technologies' Earnings History.

NanoString Technologies is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for NanoString Technologies.

NanoString Technologies will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

NanoString Technologies updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of $-2.4--2.2 for the period, compared to the Thomson Reuters consensus EPS estimate of $-2.24. The company issued revenue guidance of $118-123 million, compared to the consensus revenue estimate of $120.83 million.

1 brokerages have issued 12-month target prices for NanoString Technologies' shares. Their predictions range from $35.00 to $35.00. On average, they anticipate NanoString Technologies' stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 58.2% from the stock's current price. View Analyst Price Targets for NanoString Technologies.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NanoString Technologies.

News coverage about NSTG stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. NanoString Technologies earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for NanoString Technologies.

Some companies that are related to NanoString Technologies include Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Regenxbio (RGNX), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Alector (ALEC), Editas Medicine (EDIT), Sangamo Therapeutics (SGMO), Aerie Pharmaceuticals (AERI) and Fate Therapeutics (FATE).

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Bank Of The Ozarks (OZRK), Designer Brands (DBI) and Eaton Vance Floating-Rate Income Trust (EFT).

NanoString Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.40%) and Truvestments Capital LLC (0.01%). Company insiders that own NanoString Technologies stock include Charles P Waite, Jr, David W Ghesquiere, K Thomas Bailey, Kirk Malloy, Lifesciences Ii LP Clarus, Mary Tedd Allen, Nicholas Galakatos, R Bradley Gray and William Young. View Institutional Ownership Trends for NanoString Technologies.

NSTG stock was bought by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Truvestments Capital LLC. View Insider Buying and Selling for NanoString Technologies.

Shares of NSTG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NSTG stock can currently be purchased for approximately $22.12.

NanoString Technologies has a market capitalization of $783.93 million and generates $106.73 million in revenue each year. The biotechnology company earns $-77,400,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. NanoString Technologies employs 476 workers across the globe.View Additional Information About NanoString Technologies.

The official website for NanoString Technologies is http://www.nanostring.com/.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The biotechnology company can be reached via phone at 206-378-6266 or via email at [email protected]